Hook and thesis
I am adding to my Rocket Lab (RKLB) position after the recent sell-off. Shares trade around $51.37 after tumbling from the post-peak run, leaving valuation stretched on trailing multiples but attractive from a risk/reward standpoint given a large, contracted launch backlog and a path to profitability in 2027. Technical indicators show the stock is deeply oversold, creating a tactical entry window for patient, risk-aware buyers.
The trade is not a blind ‘buy-the-dip’ play. It's a concentration of conviction plus explicit downside protection: enter at $51.37, stop at $39.50, and a long-term target of $90.00 over a 180 trading-day horizon. This captures upside from contract fulfillment, cadence improvements on launches, and optionality tied to Neutron - while accepting near-term operational and execution risk.
What Rocket Lab does and why the market should care
Rocket Lab is an end-to-end space company with two core segments: Launch Services (dedicated and rideshare missions) and Space Systems (spacecraft engineering, manufacturing and on-orbit services). The company has transitioned from a small launch provider into a multi-product aerospace firm with a growing services backlog and ambitions in medium-class reusable rockets (Neutron).
The market values Rocket Lab like a high-growth technology company rather than a conventional aerospace contractor: market capitalization sits in the low tens of billions ($30.7B enterprise value) even as the company remains loss-making on an accounting basis. Investors care because Rocket Lab is a provider of launch cadence capacity and spacecraft manufacturing - both bottlenecks in a gnarly but expanding commercial space market. Contract wins translate to near-term revenue visibility and multi-year backlog that can de-risk revenue growth.
Key fundamentals and what the numbers say
- Revenue growth: Analysts expect roughly $255.9M in the most recent quarter and $945.03M for the full year, implying continued strong top-line growth (reported consensus growth near 65% year-over-year for the recent quarter).
- Profitability and cash flow: Rocket Lab remains unprofitable on a GAAP basis (trailing EPS around -$0.26) and reported negative free cash flow of about -$371.1M. Management and sell-side models point to profitability emerging in 2027, which is central to the equity story.
- Balance sheet and liquidity: The company shows robust liquidity ratios (current ratio ~5.48, quick ratio ~4.98) and per-share cash of roughly $4.03, indicating a cushion to fund operations, R&D and the Neutron program while execution continues.
- Valuation: Price-to-sales and price-to-book are elevated (P/S ~42.7, P/B ~9.4), reflecting high expectations. Enterprise value is approximately $30.74B. These multiples imply the market is pricing meaningful success from Neutron, the Iridium acquisition and future Space Systems margins.
- Technicals and sentiment: Momentum is bearish - the 10/21-day simple moving averages are well above spot price, MACD shows bearish momentum and RSI sits in oversold territory (~26), suggesting a potential mean reversion opportunity if execution stabilizes. Short interest is meaningful but moderate in days-to-cover (~2 days) which could create episodic volatility around news flow.
Why I'm adding now
Three concrete reasons justify adding to a long position at these levels:
- Contract backlog and revenue visibility. Rocket Lab recently expanded backlog above $840M after a large repeat order from Synspective (20 launches added, total 47 launches ~ $168M) and other 2026 contract wins. That backlog translates into revenue visibility across 2028-2031 for many of these customers, which supports multiple launch cadence and spacecraft-manufacturing revenue streams.
- Oversold technical setup. RSI near 26 and sizeable gap between current price and moving averages creates a tactical buying window for disciplined traders seeking mean reversion. Volatility creates buying opportunities for size-limited additions with strict stops.
- Path to profitability and improving unit economics. Management is guiding to profitability in 2027 even after the pending Iridium deal. If Rocket Lab can scale launches and improve Space Systems margins as volume ramps, earnings could re-rate from negative EPS to positive in 2027, a key value inflection.
Valuation framing
At a $30.7B enterprise value, Rocket Lab is priced for a lot of future growth and execution success. P/S of roughly 42.7 and P/B near 9.4 are rich versus classic aerospace/defense peers, but Rocket Lab is not a classic peer - the company is expected to scale recurring launch revenue and higher-margin spacecraft services. That said, the stock's multiple embeds Neutron success and profitable integration of the Iridium acquisition. This trade is a bet that at least some of those expectations are met and that the market rewards demonstrated cadence and margin improvement.
Catalysts to drive upside (2-5)
- Operational cadence: Any acceleration or reliable cadence improvements in Electron launches and clear milestones for Neutron will materially reduce execution risk and re-rate sentiment.
- Contract announcements and backlog growth: Additional multi-launch deals like the Synspective order will extend revenue visibility and lift implied forward revenue.
- 2027 profitability guideposts: Evidence that the company is on track for positive GAAP or adjusted operating income in 2027 will be a major re-rating event.
- Successful Neutron testing milestones or a firmed maiden flight timetable earlier than the current 2027 date would materially reduce optionality discounting and lift long-term valuation.
Trade plan - actionable specifics
Entry: $51.37 (current market).
Stop loss: $39.50 (hard stop).
Target: $90.00 (primary long-term target).
Horizon and rationale: This is a long-term trade targeting a recovery and re-rating over long term (180 trading days). Expect early moves on positive news in the short term (short term - 10 trading days) and more meaningful re-rates in the mid term (mid term - 45 trading days) as backlog conversions and cadence signals arrive. The primary target of $90 is set for the long-term window; it assumes a combination of revenue realization, margin improvement and re-acceleration of investor appetite for space-growth stories.
Alternative shorter scenarios:
- Short term (10 trading days): Upside to $65 possible on any beat-and-raise or positive Neutron/operational update; trade should be actively managed in this window given headline sensitivity.
- Mid term (45 trading days): Upside to $80 if cadence and backlog conversion are steady and there are no fresh delays on Neutron beyond the announced 2027 shift.
Sizing guidance: Given high execution risk and elevated valuation, allocate no more than a defined portion of equity exposure (e.g., 1-3% of portfolio) for a core-add. Use the stop to limit absolute downside and scale out partial position into strength.
Risks and counterarguments
Any investment here is high-risk/high-reward. Key risks include:
- Program execution risk: Neutron has been delayed to 2027; further delays or cost overruns could push profitability and revenue trajectories out materially.
- Cash burn and free cash flow: The company is burning cash (free cash flow about -$371M). If cash burn accelerates or financing conditions tighten, dilution is possible and that would pressure the equity.
- High valuation sensitivity: The stock trades on elevated multiples (P/S ~42.7, P/B ~9.4). Any downside surprise to revenue or margins will be punished heavily by the market.
- Competitive pressure: Larger players like SpaceX and new entrants increasing cadence could compress Rocket Lab’s pricing power in small-to-medium launch markets.
- M&A and integration risk: The pending Iridium acquisition (multi-billion-dollar scale) complicates near-term cash flow and integration; if integration costs overshoot or synergies are delayed, earnings could be weaker than expected.
Counterargument to my thesis
A valid counterargument is that Rocket Lab is already priced as a growth darling that needs near-perfect execution to justify its valuation. If Neutron underdelivers or the Iridium deal materially increases leverage without commensurate revenue/margin benefits, the equity could re-rate significantly lower. In that scenario, even a successful backlog may not be enough to offset higher capital intensity and prolonged negative free cash flow.
What would change my mind
I would reduce conviction or close the position if any of the following occur:
- New delays announced that push Neutron beyond 2027 or show material technical setbacks in the program.
- Free cash flow trends worsen materially beyond the current run-rate without a clear financing pathway that avoids heavy dilution.
- Material contract cancellations or a sharp deterioration in the company’s launch backlog.
Conclusion and stance
Rocket Lab is an asymmetric trade at these levels: you get a sizable contracted backlog and a path to profitability against a backdrop of high execution and valuation risk. My stance is a cautious long - I am doubling down from current levels with a tight stop at $39.50 and a long-term target of $90.00 over 180 trading days. This is not a buy-and-forget; it is a risk-managed, conviction-weighted add that demands active monitoring of launch cadence, backlog growth, cash flow trajectory and Neutron program milestones.
If the company shows tangible progress toward 2027 profitability and cadence improves, the path to my target becomes credible. If the opposite happens, the stop at $39.50 preserves capital and allows re-evaluation from a lower cost basis.
TradeVae trade plan summary:
| Ticker | Entry | Stop | Target | Horizon |
|---|---|---|---|---|
| RKLB | $51.37 | $39.50 | $90.00 | Long term (180 trading days) |
Key points to watch over the next 90 days
- Operational cadence updates and any Electron launch successes or failures.
- Additional backlog announcements or cancellations.
- Liquidity and cash-flow commentary on quarterly calls.
- Neutron program milestones and timeline clarity.
Bottom line: This is a high-conviction tactical add for risk-aware investors who believe Rocket Lab can convert backlog into revenue and improve margins toward a 2027 profit inflection. Keep position sizing disciplined and respect the stop.